Clinical Trial

A Study to Assess New Formulations of TEV-56286

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-28; most recent amendment 2026-02-04.
Status change: Recruiting → Completed 2025-07-15
Trial Details
NCT Number NCT06911567
Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC
Conditions Healthy Participants
Enrollment 47 participants
Start Date 2025-03-10
Primary Completion 2025-05-22 (estimated)
Study Completion 2025-06-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-09